Patients with TP53 dysfunction, assessed by del(17p) or TP53 mutations, respond poorly to chemo-immunotherapy and fare better with the new therapies (BCR and BCL-2 inhibitors); however, it is unclear whether their response is similar to that of patients without anomalies or whether there is currently an adequate determination of TP53 dysfunction.
TP53 dysfunction in chronic lymphocytic leukemia : clinical relevance in the era of B-cell receptors and BCL-2 inhibitors / F. Morabito, M. Gentile, P. Monti, A.G. Recchia, P. Menichini, M. Skafi, M. Atrash, G. De Luca, S. Bossio, H. Al-Janazreh, S. Galimberti, Z. Salah, L. Morabito, A. Mujahed, M. Hindiyeh, M. Dono, F. Fais, G. Cutrona, A. Neri, G. Tripepi, G. Fronza, M. Ferrarini. - In: EXPERT OPINION ON INVESTIGATIONAL DRUGS. - ISSN 1354-3784. - (2020 Jun 27). [Epub ahead of print] [10.1080/13543784.2020.1783239]
TP53 dysfunction in chronic lymphocytic leukemia : clinical relevance in the era of B-cell receptors and BCL-2 inhibitors
A. Neri;
2020
Abstract
Patients with TP53 dysfunction, assessed by del(17p) or TP53 mutations, respond poorly to chemo-immunotherapy and fare better with the new therapies (BCR and BCL-2 inhibitors); however, it is unclear whether their response is similar to that of patients without anomalies or whether there is currently an adequate determination of TP53 dysfunction.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Morabito_Expert Opin Investig Drugs_2020.pdf
Open Access dal 28/06/2021
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
1.87 MB
Formato
Adobe PDF
|
1.87 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
